AIM
RNAM

AXA Investment Managers’s Avidity Biosciences RNAM Stock Holding History

AXA Investment Managers’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$4.43M Buy
+101,658
New +$4.11M 0.01% 598

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AXA Investment Managers's RNAM Position: Q3 2025 in Review

AXA Investment Managers opened a new position in Avidity Biosciences (RNAM) in Q3 2025: 101,658 shares worth $4.43M. The stake represents 0.01% of the portfolio and ranks #598 among its holdings.

272 funds tracked by Wall St. Rank hold RNAM as of Q3 2025.

  • AXA Investment Managers held 101,658 shares of Avidity Biosciences worth $4.43M as of Q3 2025.
  • Avidity Biosciences was a new AXA Investment Managers position in Q3 2025.
  • Avidity Biosciences made up 0.01% of AXA Investment Managers's portfolio in Q3 2025, its #598 holding.
  • 272 funds tracked by Wall St. Rank held Avidity Biosciences as of Q3 2025.

Based on AXA Investment Managers's 13F filing for Q3 2025, filed 14 Nov 2025.